

## Supplementary Material

**Article Title:** Aripiprazole Once-Monthly for Patients Diagnosed With Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

**Authors:** Leslie Citrome, MD, MPH; Karimah S. Bell Lynum, PharmD; Zhen Zhang, PhD; Norman Atkins, Jr., PhD; Anne M. Hutson Walker, PhD; and Murat Yildirim, MD, PhD

**DOI Number:** 10.4088/JCP.26m16359

### **LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE**

1. [Table 1](#) Patient Demographics and Baseline Clinical Characteristics in the Acute and Maintenance Studies
2. [Table 2](#) Summary of Additional Efficacy Outcomes and Corresponding NNT Values in the Acute Study

### **DISCLAIMER**

This Supplementary Material has been provided by the authors as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

## Supplementary Material

**Supplementary Table 1. Patient Demographics and Baseline Clinical Characteristics in the Acute and Maintenance Studies<sup>a</sup>**

<b>Acute study</b>	<b>AOM 400 (n = 168)</b>	<b>Placebo (n = 172)</b>
Age, years	42.1 (11.0)	42.7 (10.9)
Female, n (%)	38 (22.6)	33 (19.2)
BMI, kg/m <sup>2</sup>	28.4 (5.6)	28.5 (5.2)
Age at first diagnosis of schizophrenia	24.4 (8.3)	24.0 (9.3)
PANSS total score	103 (11.3)	104 (11.0)
Conceptual disorganization item score	5.1 (0.3)	5.1 (0.3)
Hallucinatory behavior item score	5.3 (0.5)	5.3 (0.5)
Suspiciousness/persecution item score	5.3 (0.4)	5.3 (0.4)
Unusual thought content item score	5.1 (0.3)	5.1 (0.4)
CGI-S score	5.2 (0.5)	5.2 (0.5)
<b>Maintenance study</b>	<b>(n = 269)</b>	<b>(n = 134)</b>
Age, years	40.1 (11.0)	41.7 (10.5)
Female, n (%)	107 (39.8)	55 (41.0)
BMI, kg/m <sup>2</sup>	28.1 (6.9)	29.5 (7.5)
Age at first diagnosis of schizophrenia	25.8 (8.3)	26.5 (8.8)
PANSS total score	54.5 (12.0)	54.4 (11.6)
Conceptual disorganization item score	1.9 (0.9)	2.0 (0.9)
Hallucinatory behavior item score	1.7 (0.9)	1.7 (0.9)
Suspiciousness item score	2.2 (0.8)	2.1 (0.9)
Unusual thought content item score	1.9 (0.9)	1.9 (0.9)
CGI-S score	2.9 (0.8)	2.9 (0.8)
CGI-I score	3.0 (1.0)	3.1 (1.0)
CGI-SS score	1 (0)	1 (0)

<sup>a</sup>Data are shown as mean (standard deviation), unless otherwise stated.

Abbreviations: AOM 400= aripiprazole once-monthly 400 mg, BMI = body mass index, CGI-I = Clinical Global Impressions – Improvement, CGI-S = Clinical Global Impressions – Severity of Illness; CGI-SS = Clinical Global Impression for Severity of Suicidality, PANSS = Positive and Negative Syndrome Scale.

**Supplementary Table 2. Summary of Additional Efficacy Outcomes and Corresponding NNT Values in the Acute Study**

	Rate, n (%)		NNT	95% CI
	AOM 400 (n = 162)	Placebo (n = 167)		
Patients with a $\geq 30\%$ reduction in PANSS total score at week 4	28 (17.3)	17 (10.2)	15	ns
Patients with a $\geq 30\%$ reduction in PANSS total score at week 6	36 (22.2)	23 (13.8)	12	6–540
Patients with a $\geq 30\%$ reduction in PANSS total score at week 8	46 (28.4)	23 (13.8)	7	5–17
Patients with a $\geq 30\%$ reduction in PANSS total score at week 12	56 (34.6)	26 (15.6)	6	4–11

Abbreviations: AOM 400 = aripiprazole once-monthly 400 mg, CI = confidence interval, NNT = number needed to treat, ns = not significant, PANSS = Positive and Negative Syndrome Scale.